Crosstrees Medical, Inc. Awarded U.S. Patent for Spinal Disc Therapy Devices

Share this story with your network

BOULDER, Colo.–(BUSINESS WIRE)–Crosstrees Medical, Inc., a development stage company conducting clinical studies in the treatment of vertebral compression fractures, today announced that it has been granted a patent from the United States Copyright and Patent Office for its innovative delivery technology applied to the spinal disc. The patent, U.S. Patent No. 7,993,345, was granted August 9, 2011 for “Device and Method for Distraction of the Spinal Disc Space.”

“We are pleased with the issuance of this patent and the expansion of our defining intellectual property to therapeutic applications for degenerative disc disease.”

Research and Development staff at Crosstrees developed the patented technology to address the need for improved delivery of therapeutic agents to the damaged spinal disc. Devices using Crosstrees PodTM technology feature a polymer material constructed to control the delivery of biomaterials to selected areas of the body, with a focus on treatment of degenerative spine conditions. Following delivery of therapeutic agents, the polymer construct is opened and removed from the anatomic site, leaving only the filler material within the anatomic site.

“The Crosstrees PodTM System offers multiple opportunities for improved surgical outcomes for patients with degenerative spine conditions,” said Robert Scribner, President & CEO of Crosstrees Medical, Inc. “We are pleased with the issuance of this patent and the expansion of our defining intellectual property to therapeutic applications for degenerative disc disease.”

In the USA, the Crosstrees PodTM System is being evaluated in an IDE clinical study being conducted in support of a future 510(k) market clearance submission to the U.S. Food and Drug Administration (FDA). Details of the IDE study may be viewed at http://clinicaltrials.gov/ct2/show/NCT00933036?term=Crosstrees&rank=1. Estimates for the incidence of pathologic vertebral compression fractures in the USA by the National Osteoporosis Foundation exceed 700,000 annually. Crosstrees is developing and commercializing a product portfolio that uses its patented extractable device technology to address the increasing demand for improved vertebral fracture treatment. The company has developed a portfolio of issued patents in the United States, EU, China, and Taiwan, with additional applications pending for a broad portfolio of therapeutic devices and methods of use.

For more information, visit www.crosstreesmedical.com.

Leave a Comment

Your email address will not be published. Required fields are marked *

*